Treatment of bacterial dysentery
AssigneeSynsorb Biotech, Inc.
InventorsDavid J. Rafter, Bradley G. Thompson, Peter N. McLaine, Peter C. Rowe, Elaine Orrbine, Terrance P. Klassen, Glen D. Armstrong, Paul R. Goodyer, Andrew M. MacKenzie, George A. Wells, Hermy Lior, Francois Auclair
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for the neutralization of shiga-like toxins (SLT) associated with enteric E. coli infection which methods inhibit progression of this infection into hemolytic uremic syndrome (HUS).
Claims13
A method for inhibiting the development of hemolytic uremic syndrome in a patient arising from enterohemorrhagic E. coli infection mediated by shiga-like toxins which method comprises administering to said patient within about 3 days of presentation of the infection an effective amount of a pharmaceutical composition comprising a pharmaceutically inert affinity support comprising an .alpha.Gal(1.fwdarw.4).beta.Gal subunit which is bound to said support through a non-peptidyl linker arm, wherein said subunit binds SLT toxin.
A method for inhibiting the development of hemolytic uremic syndrome in a patient presenting with an enterohemorrhagic E. coli infection mediated by shiga-like toxin, which method comprises administering to the patient within about 3 days of presentation of the infection an effective amount of a pharmaceutical composition comprising a pharmaceutically inert affinity support comprising an oligosaccharide selected from the group consisting of .alpha.Gal(1.fwdarw.4).beta.Gal, .alpha.Gal(1.fwdarw.4).beta.Gal(1.fwdarw.4).beta.GlcNAc which oligosaccharide is bound to the support through a non-peptidyl linker arm.
Dependencies are inferred from the claim text.